Australia markets closed
  • ALL ORDS

    7,320.70
    +8.70 (+0.12%)
     
  • ASX 200

    7,060.70
    +5.30 (+0.08%)
     
  • AUD/USD

    0.7729
    +0.0022 (+0.29%)
     
  • OIL

    62.09
    +0.66 (+1.07%)
     
  • GOLD

    1,772.20
    -9.80 (-0.55%)
     
  • BTC-AUD

    64,348.38
    -6,533.90 (-9.22%)
     
  • CMC Crypto 200

    1,141.98
    +18.08 (+1.61%)
     
  • AUD/EUR

    0.6411
    +0.0003 (+0.05%)
     
  • AUD/NZD

    1.0778
    +0.0022 (+0.21%)
     
  • NZX 50

    12,650.64
    +73.16 (+0.58%)
     
  • NASDAQ

    13,884.10
    +121.74 (+0.88%)
     
  • FTSE

    6,926.27
    -11.97 (-0.17%)
     
  • Dow Jones

    34,009.08
    +193.18 (+0.57%)
     
  • DAX

    15,245.18
    -75.34 (-0.49%)
     
  • Hang Seng

    29,078.75
    +323.41 (+1.12%)
     
  • NIKKEI 225

    29,020.63
    -167.54 (-0.57%)
     

Why New COVID Strains May Mean More Revenue for Pfizer and Moderna

Adria Cimino, The Motley Fool
·4-min read

In this Motley Fool Live video, recorded on Feb. 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss how Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and others are faring, how they plan to deal with new variants, and what all of this means for revenue. Corinne Cardina: There has been a lot of different research about which vaccines, how they're holding up against different variants.